Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infliximab in Pemphigus Vulgaris
NCT00283712Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2006
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of infliximab in pemphigus vulgaris (PV), sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2006; status: completed.
02
Drugs
infliximab
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on NCT00283712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283712.